KRTAP20-1

Across TCGA pan-cancer cohorts, KRTAP20-1 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated KRTAP20-1 data layer compared with 3 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher KRTAP20-1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP20-1 expression acts as an unfavorable survival marker, although some lineages such as PRAD show a favorable association.

STAD, BRCA, and PAAD are the cancer types where KRTAP20-1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.400	0.595	.005	90	view →
BRCA	OS	Tertile	II,III,IV	0.682	0.914	<.001	48	view →
PAAD	OS	Tertile	II,III,IV	0.210	0.556	.007	18	view →
LIHC	DFS	Tertile	All	0.170	0.443	.010	18	view →
MESO	OS	Tertile	II,III,IV	0.270	0.440	.037	12	view →
PCPG	DFS	Tertile	All	0.086	0.845	.022	9	view →
SARC	DFS	Tertile	All	0.121	0.591	.042	9	view →
PRAD	DFS	Tertile	All	1.000	0.928	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KRTAP20-1–STAD (OS)

Open the STAD breakdown →